Abbott Laboratories ABT

Abbott Laboratories (Abbott) se dedica a la investigación, desarrollo, fabricación y venta de una línea diversificada de productos de cuidado de la salud. La Compañía opera a través de cuatro segmentos: Productos Farmacéuticos Establecidos, Productos de Diagnóstico, Productos Nutricionales y Dispositivos Médicos. Sus productos incluyen una línea de dispositivos de gestión del ritmo, electrofisiología, insuficiencia cardíaca, vascular y estructural para el tratamiento de enfermedades cardiovasculares, y productos para el cuidado de la diabetes para personas con diabetes, así como dispositivos de neuromodulación para el manejo del dolor crónico y trastornos del movimiento. Los productos de la Compañía se venden directamente a mayoristas, distribuidores, agencias gubernamentales, instalaciones de atención médica, farmacias y minoristas independientes desde centros de distribución de propiedad de Abbott y almacenes públicos. Ofrece productos cardiovasculares y metabólicos, incluyendo Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens y Synthroid.

Con 10 acciones de ABT (USD 972,41) habrías recibido USD 24,80 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

  Dexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.

  

• Zacks Investment Research 2 oct

  4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

  With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

  

• GlobeNewswire Inc. 1 oct

  Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

  The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

  

• Zacks Investment Research 30 sept

  Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know

  Abbott stock closed down 2.1%, underperforming the S&P 500's 0.25% loss. The stock has declined 7.33% over the past month, significantly lagging the Medical sector. Upcoming earnings are expected to show $1.43 EPS (10% YoY growth) and $12.91B revenue (13.52% increase). Abbott holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.28, trading at a discount to its industry average.

  

• GlobeNewswire Inc. 28 sept

  Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032

  The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.